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Unusual clinical course
Delta-8 tetrahydrocannabinol (delta-8 THC) is an isomer of delta-9-tetrahydrocannabinol (delta-9 THC), the primary psychoactive cannabinoid in the marijuana plant. Typically found at lower concentrations in marijuana,
delta-8 THC exhibits psychoactive properties similar to delta-9 THC. Products containing delta-8 THC are readily available across the US and currently there is a lack of available conﬁrmatory testing speciﬁc to delta-8 THC
as there is cross-reactivity to other naturally occurring cannabinoids in standard immunoassays. Pediatric exposures to this substance are on the rise.
We present a case with laboratory conﬁrmation of a previously healthy 2-year-old girl ingesting approximately
15 mg/kg of delta-8 THC gummies. The patient arrived minimally responsive and requiring intubation for encephalopathy. Laboratory conﬁrmation of delta-8 THC exposure is not routinely available with common testing modalities. A urine drug screen preformed in the hospital was positive for delta-9 THC. With the collaboration of the Drug Enforcement Administration’s Toxicology Testing Program, detection and conﬁrmation of
delta-8 THC was performed in the serum and urine using liquid chromatography-quadrupole time-of-ﬂight
mass spectrometry.
The prevalence of delta-8 THC-containing products in the illicit drug market is increasing rapidly. Delta-8 THC
products are now available in gas stations and in headshops. The clinical presentation of delta-8 THC exposure is similar to known eﬀects of delta-9 THC exposure. These similarities limit the clinicians’ abilities to determine the speciﬁc substance ingested. Symptomatic and supportive care remains an eﬀective treatment for
cannabinoid toxicity.
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Background

Table 1. Laboratory results.

Delta-8-tetrahydrocannabinol (delta-8 THC) is an isomer of delta-9-tetrahydrocannabinol (delta-9 THC). While both substances
are found in the marijuana plant, delta-8 THC is typically found
in much lower concentrations than delta-9 THC [1,2]. Delta-9
THC, the primary psychoactive cannabinoid in marijuana, is responsible for a range of symptoms observed following exposure in children, including simple diﬃculty ambulating, excessive sleepiness, respiratory depression, or seizures [3,4]. Less
commonly, children have developed coma and required intubation and the use of a ventilator [4]. The increased availability of THC-containing products, especially those appealing to
children such as gummies, candies, or cookies, have resulted in
an increase in accidental exposure to younger individuals. The
recent increase in marketing of delta-8 THC-containing edibles
and vaping products has resulted in both adult and pediatric
exposure resulting in adverse eﬀects, including children requiring intensive care unit (ICU) admissions following exposure [5].

.L^P =P[Z]_
Our patient was a previously healthy 2-year-old girl who was
transferred via air ambulance for sedation and decreased responsiveness following a reported “CBD edibles” ingestion.
Ingestion was determined to be approximately 45 minutes
prior to arrival at the local hospital. On arrival to the local
emergency department (ED), the child was minimally responsive to stimuli, with a Glasgow Coma Scale of three. The patient weighed 15.3 kg. Vitals were a heart rate of 136 beats
per minute, with an O2 saturation of 98% on room air. Given
her acute encephalopathy, there was concern for airway compromise and she was intubated using fentanyl and ketamine.
On arrival to the ED, she remained minimally responsive but
did have spontaneous eye opening and upper-extremity movements. The patient was placed on dexmedetomidine drip at
0.5 mcg/kg/h for light sedation and admitted to the pediatric intensive care unit.
The toxicology service was consulted and presented to bedside
to evaluate the patient. The father stated he had purchased
delta-8 THC gummies from a local gas station, leaving the unopened product on a desk. Later, the family noted the patient
was behaving oddly and was lethargic. The family investigated and found an open empty package of gummies with three
spilled on the ﬂoor. The package contained 12 gummies, each
containing 25 mg of delta-8 THC according to the manufacture’s labeling. The father estimated the ingestion to be approximately nine gummies, yielding an estimated total dose
of 225 mg of delta-8 THC (14.7 mg/kg). The father denied access to other marijuana products in the home.
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Sample

Serum

Urine
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Delta-8-THC

107.6

11-nor-9-carboxy-delta8-THC

746.5

11-nor-9-carboxy-delta8-THC

1550

An initial urine drug screen (UDS) was performed via enzymelinked immunoassay (ELISA), which was positive for cannabinoids and fentanyl. Reﬂex liquid chromatography-tandem
mass spectrometry (LC-MS/MS) detected fentanyl at 5 ng/ml
and carboxy-THC at >400 ng/ml. Comprehensive urine drug
testing by gas chromatography-mass spectrometry (GC-MS)
revealed ketamine, fentanyl, and cannabinoids. Her complete
blood count and comprehensive metabolic panel did not reveal any signiﬁcant abnormalities.
The child’s biological samples and the gummies were referred
to the Drug Enforcement Administration’s Toxicology Testing
Program (DEA TOX) for analysis. Comprehensive drug analysis
using liquid chromatography-quadrupole time-of-ﬂight mass
spectrometry (LC-QTOF/MS) conﬁrmed delta-8 THC and the
absence of delta-9 THC in the gummy. The plasma concentration was 107.6 ng/mL delta-8 THC and 746.5 ng/mL 11-nor9-carboxy-delta-8-THC, while the urine concentration was
1550 ng/mL 11-nor-9-carboxy-delta-8-THC. Results are summarized in Table 1.
The patient was extubated approximately 10 hours after arrival at the pediatric intensive care unit (PICU) and monitored on
the pediatric ﬂoor for an additional 24 hours. Her mental status changes resolved, GCS returned to 15, and she was able
to tolerate oral foods and liquids. Her mental impairment resolved after an additional 24 hours and, following recommendations by social work and pediatric forensics, she was discharged home.

Discussion
.`]]PY_ 0aTOPYNP
Research into the cannabinoid pharmacology was driven by
the discovery and isolation of the two most common cannabinoids, delta-9 THC and cannabidiol. Since their discovery in
the 1930s and 1940s, many other cannabinoids have been
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identiﬁed. Cannabinoid concentrations vary greatly between
plants and, although not a recent discovery, delta-8 THC has
more recently gained popularity, with articles published in mainstream media. Initial investigations into delta-8 THC began in
the 1970s with investigation of antineoplastic and antiemetic
properties in animal models [6-8]. Delta-8 THC occurs in trace
amounts in the cannabis plant and could be a degradation
product of delta-9 THC after long-term storage and aging [2].

states [12]. Following intravenous administration of delta-8
THC to three males, the qualitative symptoms experienced
were similar to those reported from delta-9 THC. While subjects within the study reported that delta-8 THC had slightly weaker eﬀects as compared to delta-9 THC [12], the study
conducted a subjectively rated dose-response curve to compare eﬀects of both substances, with no signiﬁcant diﬀerences in dose-eﬀect curves for these two substances.

Pharmacology

A wide variety of symptoms can develop from profound delta-9 THC exposure in children, from simple diﬃculty ambulating, to excessive sleepiness, to respiratory depression [13].
Coma requiring mechanical ventilation has been rarely reported in exposed children. Symptoms can range from being
unbalanced, to any degree of sleepiness, to poor respiratory
eﬀort. Less commonly, children have developed coma and required intubation [13].

Pharmacologically, delta-8 THC, like delta-9 THC, has agonistic
properties at both the cannabinoid type 1 and type 2 receptors [8-10]. Relatively few studies have evaluated the potency of delta-8 THC compared to delta-9 THC. A study in mice
suggested near-equivalent potency of delta-8 THC vs delta-9
THC [6]. One of the mouse studies characterized three progressive stages of exposure to both delta-9 THC and delta-8 THC:
(1) irritability; (2) decrease in spontaneous activity, with hypersensitivity to auditory and tactile stimuli; and (3) marked depression of spontaneous activity, decreased awareness, loss of
muscle coordination, and reduced sensorimotor response [6]. A
higher incidence of “freezing” or immobility in delta-8 THC exposures was also documented. Additionally, hypothermia and
respiratory depression were noted with both compounds [6].
.WTYTNLW ;]P^PY_L_TZY
It has previously been reported that the psychoactive eﬀects
of delta-8 THC are qualitatively similar to delta-9 THC in children and adults [8,12]. In a small open-label study, delta-8 THC
administered as an antiemetic in pediatric oncology patients
abated vomiting in all eight individuals who received treatment. Adverse eﬀects included irritability (two subjects) and
euphoria (one subject) [8]. In a study of adult volunteers, delta-8 THC administered either orally or intravenously was reported to be slightly less potent than delta-9 THC, with an estimated potency ratio of 2: 3. In this study, six male subjects
were administered oral doses of either 20 mg of delta-8 THC,
an equal dose of delta-9 THC, or a 40-mg dose of delta-8 THC
contained in chocolate cookies. The authors stated all three
doses produced similar somatic, perceptual, and psychic effects. Somatic eﬀects appeared early and included dizziness,
dryness of mucous membranes, paresthesia, tinnitus, increased
body awareness, weakness, muscle tension or tremor, incoordination, fatigue, and sleepiness. Perceptual eﬀects appeared
concurrently with psychic eﬀects, and, although not as prominent, included blurring, vibrations, or distortions of vision, such
as altered perspectives, imagery, and enhancement of colors
or contrasts; time distortion, and decreased discrimination of
hearing. Psychic eﬀects included euphoria, tranquility, and relaxation; diﬃculty in thinking, speaking, reading, remembering;
unusually rapid ﬂow of thoughts; and dreamy, introspective
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Management
Symptomatic and supportive care remains an eﬀective treatment for cannabinoid toxicity. Gastrointestinal decontamination is generally not recommended for oral ingestions due to
the decline in mental status or acute agitation. Intravenous
ﬂuids and vasopressors can be considered for hemodynamic support, and benzodiazepines can be administered for anxiety, agitation, or seizures. The collection of drug samples in
addition to patient blood and urine may aid in further understanding eﬀects and treatment requirements [14].
?P^_TYR
There are no published case reports of delta-8 THC exposures
to date nor has there been laboratory conﬁrmation obtained.
The lack of available conﬁrmatory testing speciﬁc to delta-8
THC and its cross-reactivity to other naturally occurring cannabinoids in standard immunoassays, along with similarities in
presentation to delta-9 THC exposures, present a challenge to
properly documenting delta-8 THC intoxications [2]. Recently, an
LC-MS/MS method to conﬁrm delta-8 THC and its metabolites
in Driving Under the Inﬂuence of Drugs investigation casework
was published [15]. However, no method using LC-QTOF/MS,
as applied in our case, has previously been published.
Products
Products containing delta-8 THC are readily available across
the US via online sources, in gas stations, and in headshops.
Delta-8 THC-containing products come labeled as having metabolites with the potential to trigger drug tests for delta-9
THC and should be avoided if a drug test is imminent. Large
quantities of delta-8 THC can be purchased as edibles, various
infused plant products, via atomizer devices, tinctures, and as
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bulk product. As with delta-9 THC, concentration and labeling
varies greatly depending on the sources and manufacturer.

limiting clinician abilities to determine the speciﬁc substance
ingested. Current commercially available packaging and ﬂavoring do little to deter children from ingesting these substances.

.ZYNW`^TZY^

Statement

As the availability of delta-8 THC increases, we can anticipate
exposures to these products will increase. Currently, it is diﬃcult to diﬀerentiate delta-8 THC from delta-9 THC utilizing routine laboratory testing. The clinical presentation of delta-8 THC
exposure is consistent with the known eﬀects of delta-9 THC,

This case occurred at the University of Kentucky in the
Emergency Department and Pediatric Intensive Care Unit.
Testing was performed at the University of California, San
Francisco in the Clinical Toxicology and Biomonitoring
Laboratory.
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